Patent intelligence · US
US 12281122
PI3K inhibitors
PI3K inhibitors
Patent details — US 12281122
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 22, 2025
- Expiration
- Apr 17, 2045
- Applicant
- Cogent Biosciences, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/517
Quick answer
US 12281122 (PI3K inhibitors) is held by Cogent Biosciences, Inc.. Status: granted. Granted Apr 22, 2025. Expires Apr 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cogent Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/517
More from Cogent Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12351581
Compounds for FGFR inhibition
granted -
US 11718576
Compositions and methods comprising resveratrol
granted -
US 11339112
Compositions and methods comprising resveratrol
granted -
US 10836702
Compositions and methods comprising resveratrol
granted -
US 10449129
Encapsulates of salicylic acid and polysalicylic acid derivatives
granted -
US 10301248
Compositions and methods comprising resveratrol
granted -
US 6610295
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
expired
Frequently asked questions
What is US patent 12281122?
US 12281122 (PI3K inhibitors) is held by Cogent Biosciences, Inc.. Status: granted. Granted Apr 22, 2025. Expires Apr 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12281122?
Cogent Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 12281122 expire?
Our index shows an expiration date of Apr 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.